{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:08:04Z","timestamp":1789913284117,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T00:00:00Z","timestamp":1488931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jaad.2017.01.053","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T15:51:05Z","timestamp":1491580265000},"page":"79-87.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis"],"prefix":"10.1016","volume":"77","author":[{"given":"Joseph F.","family":"Merola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boni","family":"Elewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana","family":"Tatulych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2017.01.053_bib1","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2133.2010.09831.x","article-title":"Nail psoriasis in Germany: epidemiology and burden of disease","volume":"163","author":"Augustin","year":"2010","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.01.053_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.07.073","article-title":"Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy","volume":"57","author":"Jiaravuthisan","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.01.053_bib3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bjd.12354","article-title":"Nail psoriasis: a questionnaire-based survey","volume":"169","author":"Klaassen","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5 suppl 93","key":"10.1016\/j.jaad.2017.01.053_bib4","first-page":"S7","article-title":"Nail psoriasis","volume":"33","author":"Manhart","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.jaad.2017.01.053_bib5","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/jdv.12368","article-title":"Nail psoriasis, the unknown burden of disease","volume":"28","author":"Klaassen","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2017.01.053_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000360696","article-title":"The impact of fingernail psoriasis on patients' health-related and disease-specific quality of life","volume":"229","author":"van der Velden","year":"2014","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2017.01.053_bib7","first-page":"1","article-title":"Nail psoriasis as a severity indicator: results from the PsoReal study","volume":"2","author":"Radtke","year":"2011","journal-title":"Patient Relat Outcome Meas"},{"issue":"5","key":"10.1016\/j.jaad.2017.01.053_bib8","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/bjd.13272","article-title":"Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis","volume":"171","author":"Langenbruch","year":"2014","journal-title":"Br J Dermatol"},{"issue":"suppl 5","key":"10.1016\/j.jaad.2017.01.053_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jdv.12562","article-title":"Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review","volume":"28","author":"Rouzaud","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2017.01.053_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/jamadermatol.2014.2983","article-title":"Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation","volume":"151","author":"Crowley","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"9993","key":"10.1016\/j.jaad.2017.01.053_bib11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2017.01.053_bib12","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.01.053_bib13","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.01.053_bib14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis","volume":"49","author":"Rich","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.01.053_bib15","first-page":"563","article-title":"Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis","volume":"8","author":"Truong","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2017.01.053_bib16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1590\/abd1806-4841.20153736","article-title":"Nail involvement in adult patients with plaque-type psoriasis: prevalence and clinical features","volume":"90","author":"Schons","year":"2015","journal-title":"An Bras Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.01.053_bib17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1468-3083.2009.03426.x","article-title":"Growth rate of human fingernails and toenails in healthy American young adults","volume":"24","author":"Yaemsiri","year":"2010","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2017.01.053_bib18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jaad.2007.07.042","article-title":"Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year","volume":"58","author":"Rich","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2017.01.053_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/archdermatol.2008.600","article-title":"Evaluation of the efficacy of acitretin therapy for nail psoriasis","volume":"145","author":"Tosti","year":"2009","journal-title":"Arch Dermatol"},{"issue":"17","key":"10.1016\/j.jaad.2017.01.053_bib20","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJMoa1010858","article-title":"A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis","volume":"365","author":"Reich","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jaad.2017.01.053_bib21","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1468-3083.2010.03927.x","article-title":"Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study","volume":"25","author":"Gumusel","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2017.01.053_bib22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/120347540400800208","article-title":"Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol","volume":"8","author":"Feliciani","year":"2004","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"6","key":"10.1016\/j.jaad.2017.01.053_bib23","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-016-0564-5","article-title":"Nail psoriasis: a review of treatment options","volume":"76","author":"Pasch","year":"2016","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.jaad.2017.01.053_bib24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bjd.12664","article-title":"Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes","volume":"170","author":"Augustin","year":"2014","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.01.053_bib25","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaad.2014.02.010","article-title":"Scoring nail psoriasis","volume":"70","author":"Klaassen","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.01.053_bib26","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral\u00a0Janus kinase inhibitor, for the treatment of chronic plaque\u00a0psoriasis: long-term efficacy and safety results from\u00a02\u00a0randomized phase-III studies and 1 open-label long-term extension study","volume":"74","author":"Papp","year":"2016","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217301470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217301470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:43:22Z","timestamp":1759272202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217301470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0190962217301470"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.01.053","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.01.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}